Immunotherapy for Inhalant Allergy
Introduction
Introduction
- Allergic rhinitis (AR) and allergic asthma (AA) are caused by an immunoglobulin E (IgE) mediated inflammatory response to proteins (or glycoproteins) carried by inhaled organic particles such as pollen, animal dander, mold spores, and/or mite/insect debris.
- Inhalant allergies can be treated by immunotherapy, pharmaceuticals, or by reducing environmental exposure to the allergen.
- Inhalant allergen immunotherapy (AIT) is administered to millions of patients for AR and AA and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT).
- Variability in the initiation and delivery of safe and effective immunotherapy provides opportunities for evidence-based recommendations to improve patient care.
Treatment
Treatment
...iations and Definitions of Common T...
...Summary of Guideline Key Action Statements...
...sessment...
...y for Allergen ImmunotherapyClinicians...
.... Who should not get Allergen ImmunotherapyCli...
.... Who may not get Allergen Immunotherapy...
...Asthma AssessmentClinicians should ev...
...cation...
...tion regarding SLIT versus SCITCli...
...egarding Preventive Qualities of Allergen Imm...
...reatment
...-/Co-Seasonal TherapyClinicians who administer S...
...electing Clinically Relevant AllergensClini...
...Polysensitized Patients with Limited Alle...
...ns and Allergen Immunotherapy EscalationClini...
.... Anaphylaxis Identification and M...
...esting During Allergen ImmunotherapyClin...
...r Allergen ImmunotherapyFor patients who are exp...
Table 3: Comparison of SCIT and SLIT Modaliti...
...rld Allergy Organization Subcutaneous Immun...
...igure 1. Pre-/Co-Seasonal SLIT Time CourseT...
...re 2. Anaphylaxis Diagnostic Criteria R...
...fferentiating Between Vasovagal and AnaphylaxisH...
...3. Management of AnaphylaxisReprod...
...chart Showing Key Action Statements a...